RxSight (RXST) Insider Tamara Fountain Buys 37,037 Shares
Tamara Fountain bought 37,037 shares of RxSight, Inc. on June 17, 2026, as insiders show confidence amid market challenges.
Reviewed by automated data checks against the source filing. How we make and check alerts
Tamara Fountain bought 37,037 shares of RxSight, Inc. ($RXST) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RXST is up 15.7% after 1 week, up 20.9% after 1 month and down 1.7% to date (from the $4.59 close on Jun 17, 2026).
RXST
RxSight, Inc.
Key Points
- On June 17, 2026, Tamara Fountain purchased 37,037 shares of RxSight, Inc. (NasdaqGM: RXST), valued at approximately $175,000 based on a trading price of $4.73.
- RxSight, Inc. reported a market cap of about $213.8 million and has faced challenges with a forward P/E ratio of -7.37, indicating it isn't currently profitable.
- Analysts maintain a mixed outlook on RxSight, with a consensus rating of 'Hold' and a mean price target of $7.79, suggesting cautious optimism.
Get $RXST trade alerts by text
We text you when insiders, Congress or big funds trade $RXST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated RxSight, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at RxSight, Inc.
On June 17, 2026, Tamara Fountain bought 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). This purchase adds to the activity of several other insiders who also bought shares on the same day. The stock was trading at approximately $4.73 at the time, bringing the value of Fountain's purchase to about $175,000.
Multiple Insiders Buy on the Same Day
Fountain's buy follows a trend among other insiders at RxSight. Julie Andrews, Raymond Cohen, Corley Jesse Anderson, Shweta Maniar, Link William Phd, and Robert Palmisano each purchased 37,037 shares on the same date. Raymond Cohen's purchase was slightly smaller, with 30,864 shares. This collective buying by insiders suggests a strong belief in the company's potential despite current market challenges.
Stock Performance and Market Context
RxSight's stock has seen some fluctuations, recently closing at $5.20. The shares traded as low as $4.48 over the past 52 weeks and reached a high of $13.22 during that period. This recent insider buying occurs as the company navigates a difficult market, with a forward P/E ratio of -7.37, indicating that it is not currently profitable. The stock is also trading below its 200-day moving average of $7.31.
Analysts Set New Price Targets
As of September 22, 2026, analysts have maintained a mixed outlook on RxSight. Jefferies keeps a 'Hold' rating with a price target of $5.75, down from $6.50. B of A Securities also maintains an 'Underperform' rating, lowering their target to $5.50 from $6.50. Meanwhile, Needham reiterates a 'Buy' rating with a target of $11.00, reflecting some analyst confidence in the company's future.
What RxSight, Inc. Does
RxSight, Inc. is a medical technology company based in Aliso Viejo, California. It specializes in developing light-adjustable intraocular lenses used in cataract surgery, allowing for better visual outcomes for patients. The recent insider trades suggest that executives believe in the company's strategic direction as it continues to grow in the healthcare sector.
What’s Next for RxSight
Looking ahead, investors will be watching for RxSight's next earnings report, scheduled for November 4, 2026. The recent insider transactions reflect past actions and may not indicate current positions. As the company continues to navigate its challenges, the upcoming earnings could provide further insight into its performance and strategy moving forward.
Related Filing Alerts
Source: Tamara Fountain's Form 4 filing on $RXST (Jun 17, 2026). Find the original filing: RXST Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts